Novaferon

Summary

Novaferon is a recombinant type I interferon analog produced by gene shuffling of IFN‑α. It is prescribed as an antiviral and immunomodulatory protein and has been investigated for treatment of COVID‑19 and certain cancers. The drug is approved for clinical use and can be administered by inhalation, intramuscular or subcutaneous injection.

Mechanism of Action

Novaferon mimics type I interferons by binding the IFN‑α/β receptor (IFNAR) on target cells, triggering the JAK‑STAT signaling cascade. This induces expression of interferon‑stimulated genes that establish an antiviral state, inhibit viral replication, and block entry of SARS‑CoV‑2. In immune cells, type I IFN signaling enhances natural‑killer cell activation, cytokine release (e.g., IFN‑γ, perforin, granzyme B) and modulates T‑cell subsets, contributing to antitumor activity.

What the Research Shows

In vitro studies reported that Novaferon inhibits SARS‑CoV‑2 replication (EC50 ≈ 1 ng/mL) and prevents viral entry (EC50 ≈ 0.1 ng/mL). A randomized open‑label trial of 89 COVID‑19 patients found higher viral‑clearance rates on day 6 for Novaferon alone (50 %) or with lopinavir/ritonavir (60 %) versus lopinavir/ritonavir alone (24 %). Median clearance time was reduced by three days. A separate cohort of 170 patients receiving lopinavir/ritonavir plus Novaferon showed shorter time to negative PCR (median 6 days vs 9 days) and reduced hospital stay. In oncology, a phase II trial in metastatic colorectal cancer showed moderate disease‑control rates (44 % at six weeks) with Novaferon, increased NK cell counts and decreased regulatory T cells, but no overall‑survival benefit. Engineered NK92 cells expressing Novaferon demonstrated enhanced pan‑cancer cytotoxicity in vitro and tumor‑growth inhibition in xenograft models without systemic toxicity.

Reported Benefits

Clinical data suggest Novaferon can accelerate SARS‑CoV‑2 clearance and shorten hospitalization when added to standard antiviral regimens, likely reflecting its potent antiviral activity observed in cell culture. In cancer settings, Novaferon may modestly improve disease‑control rates and boost innate immune parameters such as NK‑cell activity, indicating potential immunotherapeutic benefit. Engineered NK cells expressing Novaferon have shown robust antitumor effects in pre‑clinical models.

Limitations of the Evidence

Evidence for Novaferon’s efficacy is limited to small, open‑label studies without blinding or large‑scale randomization, and outcomes focus on virological clearance rather than mortality or long‑term recovery. The cancer trial did not demonstrate a survival advantage, and the sample size was modest. Comparative data versus other interferons or antivirals are lacking, and the pre‑clinical NK‑cell work has not yet been translated into human trials. Regulatory approval appears unrelated to COVID‑19, limiting its indicated use.

Safety Considerations

Novaferon was generally well tolerated in the reported studies. Adverse events in the colorectal‑cancer trial included influenza‑like symptoms, transient bone‑marrow suppression, liver‑function abnormalities and gastrointestinal discomfort. No serious safety signals were reported in the COVID‑19 trials, but monitoring for typical interferon‑related effects (fever, fatigue, hematologic changes) is advisable. Caution may be warranted in patients with pre‑existing autoimmune disease or hepatic impairment, although specific contraindications were not detailed in the abstracts.

How It Is Administered

Novaferon is supplied for injection and can be delivered by subcutaneous or intramuscular routes. In clinical studies for COVID‑19, it has also been administered via inhalation to target the respiratory tract. Formulations are protein‑based solutions prepared under sterile conditions; dosing schedules varied across trials (e.g., twice or three times weekly injections).

Routes of Administration

Goals & Uses

• Chronic Hepatitis C treatmentAntiviralModerate
• Antitumor activityOncologyLow
• COVID‑19 treatmentAntiviralModerate
• Chronic Hepatitis B treatmentAntiviralModerate
• ImmunomodulationImmunologyLow
• Broad‑spectrum antiviral therapyAntiviralLow
• COVID-19 antiviral therapyAntiviralLow

Contraindications

• Severe autoimmune diseaseImmunologicalModerate
• Severe psychiatric disordersPsychiatricHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Severe cytopeniasHematologicModerate
• Severe hepatic decompensationHepatic ImpairmentHigh
• Autoimmune hepatitisHepatic / AutoimmuneHigh
• Known hypersensitivity to interferon productsAllergyHigh
• Hypersensitivity to interferonsAllergyHigh

Adverse Effects

• Flu-like symptomsSystemic/ImmunologicalCommon
• Injection site reactionsLocalCommon
• Neuropsychiatric effectsNeurological / PsychiatricUncommon
• Thyroid dysfunctionEndocrineUncommon
• Flu‑like symptoms (fever, myalgia)SystemicCommon
• MyelosuppressionHematologicCommon
• Injection site reactionLocalCommonRedness, swelling, itching, bruising, or pain at the injection site
• Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers

Drug Interactions

• Live vaccinesLow
• Zidovudine (AZT)Moderate
• Immunosuppressants (e.g., cyclosporine)Moderate
• RibavirinLow
• TheophyllineModerate
• ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk

Population Constraints

• PregnancyReproductive SafetyRelative
• Renal impairmentOrgan ImpairmentRelative
• Patients with autoimmune conditionsImmunologicRelative
• Pediatric patientsAgeRelative
• Pregnant or lactating womenReproductiveAbsolute
• Elderly patientsAgeRelative
• Pediatric patients (<12 years)PediatricRelative

Regulatory Status

• European UnionUnapprovedNot authorized in EU member states.
• United StatesUnapprovedInvestigational use only.
• United KingdomUnapprovedNo marketing authorization.

Approved for clinical use in China; not approved by FDA, EMA, or MHRA.

Evidence & Sources

• SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial
  Journal ArticleModerateZheng F, et al.2020-01-01T00:00:00.000000Z
• Recent biotechnological approaches for treatment of novel COVID-19: from bench to clinical trial
  Journal ArticleModerateMousavi SM, et al.2021-01-01T00:00:00.000000Z
• Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19
  Journal ArticleLowQu J, et al.2021-01-01T00:00:00.000000Z
• Novaferon gene modification promotes NK92 cell anti-tumor activity
  Journal ArticleLowZhang W, et al.2023-01-01T00:00:00.000000Z
• Phase II Study of Recombinant Antitumor and Antivirus Protein Injection Compared With Placebo in Metastatic Colorectal Cancer After Failure of Standard Treatment
  Journal ArticleModerateJia R, et al.2015-01-01T00:00:00.000000Z
• Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials
  Journal ArticleHighPatel TK, et al.2021-01-01T00:00:00.000000Z

Frequently Asked Questions